Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.38 |
| ▸ | GLS | O94925 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5204542 | 0.85 | L3MBTL1 (0.42) | CYP2C9CYP3A4LIPGALDH1A1LMNA | |
| SCHEMBL4803556 | 0.84 | CYP3A4 (0.52) | CYP2D6CYP2C9CYP2C19CYP3A4NPC1 | |
| SCHEMBL5214004 | 0.83 | HDAC1 (0.45) | GLS | |
| SCHEMBL4808023 | 0.82 | CYP2D6 (0.45) | CYP2D6CYP2C9CYP2C19CYP3A4NPC1 | |
| SCHEMBL7423044 | 0.82 | CYP2D6 (0.45) | CYP2D6CYP2C9CYP2C19CYP3A4NPC1 | |
| Trifluoroacetic Acid SCHEMBL4809424 | 0.81 | CYP3A4 (0.47) | CYP2D6CYP2C9CYP2C19CYP3A4NPC1 | |
| Trifluoroacetic Acid SCHEMBL4807315 | 0.81 | CYP3A4 (0.47) | CYP2D6CYP2C9CYP2C19CYP3A4NPC1 | |
| SCHEMBL6992189 | 0.81 | CYP2D6 (0.47) | CYP2D6CYP2C9CYP2C19CYP3A4NPC1 | |
| SCHEMBL6990072 | 0.81 | L3MBTL1 (0.42) | CYP2C9CYP3A4LIPGNPC1ALDH1A1 | |
| SCHEMBL7122981 | 0.79 | CYP3A4 (0.52) | CYP2D6CYP2C9CYP2C19CYP3A4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343561-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2007-02-28 | — | — | EP | disclosed |
| EP-1240154-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2007-02-28 | — | — | EP | disclosed |
| US-7157585-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2007-01-02 | — | — | US | disclosed |
| US-20050215587-A1 | Serine protease inhibitors | LIVELY SARAH E | 2005-09-29 | — | — | US | disclosed |
| US-6916957-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2005-07-12 | — | — | US | disclosed |
| US-20030018059-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215587-A1 | Serine protease inhibitors | PRSS1, TPSAB1, CMA1 | CYP2D6 786/4885CYP2C9 1641/4885CYP2C19 1144/4885 |
| US-20030018059-A1 | Serine protease inhibitors | TPSAB1, PRSS1, SERPINB1 | CYP2D6 477/4885CYP2C9 1372/4885CYP2C19 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.